Ems-Chemie Holding AG
Ems-Chemie Holding AG (EMSHF) Financial Performance & Income Statement Overview
Review Ems-Chemie Holding AG (EMSHF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Ems-Chemie Holding AG (EMSHF) Income Statement & Financial Overview
View the income breakdown for Ems-Chemie Holding AG EMSHF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $984.14M | $1.09B | $1.006B | $514.99M |
| Cost of Revenue | $984.14M | $0.00 | $232.36M | $232.36M |
| Gross Profit | $0.00 | $1.09B | $773.60M | $282.63M |
| Gross Profit Ratio | $0.00 | $1.00 | $0.77 | $0.55 |
| R&D Expenses | $0.00 | $0.00 | $23.08M | $23.08M |
| SG&A Expenses | $1.42B | $1.54B | $121.27M | $121.27M |
| Operating Expenses | $711.39M | $767.70M | $768.79M | $177.84M |
| Total Costs & Expenses | -$736.48M | $795.19M | $793.42M | $410.20M |
| Interest Income | $8.44M | $3.41M | $0.00 | $1.68M |
| Interest Expense | $98000.00 | $1.81M | $2.00M | $0.00 |
| Depreciation & Amortization | $25.09M | $27.49M | $24.63M | $10.11M |
| EBITDA | $285.18M | $318.34M | $116.66M | $116.66M |
| EBITDA Ratio | $0.29 | $0.29 | $0.24 | $0.23 |
| Operating Income | $247.65M | $291.44M | $212.55M | $106.55M |
| Operating Income Ratio | $0.25 | $0.27 | $0.21 | $0.21 |
| Other Income/Expenses (Net) | $12.34M | -$2.40M | -$106.08M | -$86500.00 |
| Income Before Tax | $259.99M | $289.04M | $211.93M | $106.47M |
| Income Before Tax Ratio | $0.26 | $0.27 | $0.21 | $0.21 |
| Income Tax Expense | $45.84M | $37.07M | -$2.27M | $1.14M |
| Net Income | $211.40M | $249.39M | $211.58M | $106.29M |
| Net Income Ratio | $0.21 | $0.23 | $0.21 | $0.21 |
| EPS | $9.04 | $10.66 | $9.09 | $4.54 |
| Diluted EPS | $9.04 | $10.66 | $9.09 | $4.54 |
| Weighted Avg Shares Outstanding | $23.39M | $23.39M | $23.39M | $23.40M |
| Weighted Avg Shares Outstanding (Diluted) | $23.39M | $23.39M | $23.39M | $23.39M |
Financial performance has remained strong, with revenue growing from $514.99M in Q3 2023 to $984.14M in Q4 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $247.65M in Q4 2024, holding a steady 25% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $285.18M. Net income dropped to $211.40M, keeping EPS at $9.04. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan